ANGPT2 (Angiopoietin 2)

In this experimental model, experimental periodontitis was accompanied by concurrent increases in both local and systemic ANGPTL2 expression and accelerated growth of colorectal tumors. These findings suggest a potential association between periodontal inflammation, increased ANGPTL2 levels, and colorectal tumor progression.

Furthermore, ANGPT2 expression was significantly associated with sensitivity to chemotherapeutic drugs. To summarize, overexpression of ANGPT2 in ESCA is associated with an unfavorable prognosis and compromised tumor immunity.

NOS3, VEGFR-2, and ANGPT2 levels correlated inversely with tumor reduction after chemotherapy. These exploratory findings highlight EV proteomics as a minimally invasive platform for potential SCLC diagnosis and monitoring.

The complete response (CR) rate was 33.3% in the high-level group versus 66.7% in the low-level group (p = 0.003), and the overall response (OR) rate was 35.9% versus 74.4% (p = 0.001). CSF exosomal ANGPTL2 is a novel, independent prognostic marker in PCNSL.

ANGPT2 rs2959822 influences the survival outcomes of patients with prostate cancer undergoing ADT. In addition to angiogenesis, ANGPT2 plays a critical role in prostate cancer progression by promoting EMT and modulating the tumor immune microenvironment.

JDF exhibits efficacy in reducing hypoxia-induced angiogenesis in HCC through a mechanism involving the Aurora A/STAT3/IL-8 signaling pathway. Therefore, JDF holds promise as a potential therapeutic approach for targeting HCC angiogenesis. Please cite this article as: Zhong MF, Luo YJ, Guo YY, Xiang S, Lin WF. Jiedu Fang inhibits hypoxia-induced angiogenesis in hepatocellular carcinoma by targeting Aurora A/STAT3/IL-8 signaling pathway. J Integr Med. 2025; Epub ahead of print.

ANGPT2 demonstrates potential as a biomarker for cancer diagnosis and prognosis, with evidence suggesting its involvement in immune microenvironment regulation and associated gene networks. Therapeutic approaches targeting ANGPT2, either as a stand-alone treatment or in combination with immunotherapies, could offer new and effective strategies for future cancer treatments.

Multimodal MC was administered continuously, combining low doses of capecitabine, cyclophosphamide, and aspirin. The presence of liver metastases, baseline plasmatic levels of Ang2 and CXCL14, as well as the induction of PD1 on T-cells are potential biomarkers for efficacy. These results feature a potential subset of diseases where MC might be a promising cost-effective and well-tolerated therapeutic option.

Finally, through the investigation of the ubiquitin-mediated degradation pathway of OGDH, it was demonstrated that ANGPT2 inhibited the protein degradation of OGDH via deubiquitination, thereby maintaining its stability. In summary, UL82 promotes CRC cell proliferation by upregulating ANGPT2, which inhibits the ubiquitin-mediated degradation of OGDH, suggesting that targeting the UL82/ANGPT2/OGDH axis may offer a potential clinical strategy for the diagnosis of CRC.

BMI1 promotes angiogenesis in CRC by upregulating ANGPT2 expression. High BMI1 and ANGPT2 levels served as independent prognostic factors for tumor progression, highlighting their potential as therapeutic targets for CRC management.

TEMs promote angiogenesis in CIBT through a paracrine mechanism, and the recruitment of TEMs to CIBT is regulated by the miR-126-5p/TRPS1/ANGPT2 pathway.

Currently, monotherapy with PD-1/PD-L1 inhibitors, or their combination with bevacizumab, is considered the standard therapeutic approach for LUAD...Functionally, IFN-γ limits the migration, proliferation, and tube formation of ECs. In conclusion, our results revealed a novel mechanism wherein IFN-γ-mediated inhibition of ANGPT2-Tie2 facilitates vascular normalization during immunotherapy in LUAD, which performs an essential function in the antitumor efficacy of immunotherapy.